On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Ruling Parties Hammer Out Tax Reform Outline for FY2021
December 11, 2020
- MHLW Unveils Overview of COVID-19 Vaccine Distribution Scheme in Japan
December 11, 2020
- Fukui Pref. Govt Launches On-Site Inspection at Kobayashi Kako over Itraconazole Contaminated with Sleep Inducer
December 11, 2020
- Lyrica Faces Generic Debuts in Japan amid Patent Row: December Listing
December 10, 2020
- Chuikyo Healthcare Reps Urge Minimal Scope for Off-Year Re-Pricing, Payers Grumble over Generic-Heavy Coverage
December 10, 2020
- 2-Year Extension OK’ed for Raise on R&D Tax Credit Rates, Ceiling: LDP Subcommittee
December 9, 2020
- MHLW Estimates: Off-Year Re-Pricing with Average Price Gap Threshold Likely to Hit 8,700 Products, Save 360 Billion Yen
December 9, 2020
- MHLW Ordered Label Revisions for 5 Drugs Including Alexion’s Soliris
December 9, 2020
- Adrenomedullin, Baricitinib Added to MHLW’s COVID-19 Guide
December 8, 2020
- MHLW Panel OKs Takeda’s ALK Drug, Lynparza’s Pancreatic Cancer Use; Seikagaku’s Osteoarthritis Med Put under Continued Review
December 7, 2020
- Gardasil’s Male Indication in Line for OK as Early as This Month
December 7, 2020
- Russia Willing to Transfer Tech to Japan If Its COVID-19 Vaccine Approved: Envoy
December 7, 2020
- PM Remains Mum on Expected Timeline for Vaccination Start in Japan
December 7, 2020
- PMDA to Continue Remote GCP/Compliance Inspections through June Next Year
December 7, 2020
- FY2021 Draft Budget Guidelines Say to “Appropriately Work On” Off-Year Re-Pricing: LDP Health Panel
December 4, 2020
- MHLW Aware of Challenges in Drug Price Formation in COVID-19-Hit Market: Official
December 4, 2020
- Yescarta Sails through PAFSC Review; Panel Roughly OKs Novartis’ Corrective Measures after Zolgensma Delay
December 4, 2020
- MHLW Hears Independent Monitoring Panel’s Views on “Periodic Reports”; Will Submit Proposal at Next Meeting
December 4, 2020
- Wholesalers’ Deteriorating Earnings Attributed to Compounding Reasons: JPWA
December 3, 2020
- Lilly’s Galcanezumab Clears PAFSC Review, 1st Antibody for Migraine Prevention
December 3, 2020
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…